These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
428 related articles for article (PubMed ID: 28965718)
1. Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial. Jin C; Gibani MM; Moore M; Juel HB; Jones E; Meiring J; Harris V; Gardner J; Nebykova A; Kerridge SA; Hill J; Thomaides-Brears H; Blohmke CJ; Yu LM; Angus B; Pollard AJ Lancet; 2017 Dec; 390(10111):2472-2480. PubMed ID: 28965718 [TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial. Kumar Rai G; Saluja T; Chaudhary S; Tamrakar D; Kanodia P; Giri BR; Shrestha R; Uranw S; Kim DR; Yang JS; Park IY; Kyung SE; Vemula S; Reddy E J; Kim B; Gupta BP; Jo SK; Ryu JH; Park HK; Shin JH; Lee Y; Kim H; Kim JH; Mojares ZR; Wartel TA; Sahastrabuddhe S Lancet Infect Dis; 2022 Apr; 22(4):529-540. PubMed ID: 34942090 [TBL] [Abstract][Full Text] [Related]
3. Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial. Qadri F; Khanam F; Liu X; Theiss-Nyland K; Biswas PK; Bhuiyan AI; Ahmmed F; Colin-Jones R; Smith N; Tonks S; Voysey M; Mujadidi YF; Mazur O; Rajib NH; Hossen MI; Ahmed SU; Khan A; Rahman N; Babu G; Greenland M; Kelly S; Ireen M; Islam K; O'Reilly P; Scherrer KS; Pitzer VE; Neuzil KM; Zaman K; Pollard AJ; Clemens JD Lancet; 2021 Aug; 398(10301):675-684. PubMed ID: 34384540 [TBL] [Abstract][Full Text] [Related]
4. Vaccines for preventing typhoid fever. Milligan R; Paul M; Richardson M; Neuberger A Cochrane Database Syst Rev; 2018 May; 5(5):CD001261. PubMed ID: 29851031 [TBL] [Abstract][Full Text] [Related]
6. IgA and IgG1 Specific to Vi Polysaccharide of Dahora LC; Jin C; Spreng RL; Feely F; Mathura R; Seaton KE; Zhang L; Hill J; Jones E; Alam SM; Dennison SM; Pollard AJ; Tomaras GD Front Immunol; 2019; 10():2582. PubMed ID: 31781100 [TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials. Bhutta ZA; Capeding MR; Bavdekar A; Marchetti E; Ariff S; Soofi SB; Anemona A; Habib MA; Alberto E; Juvekar S; Khan RM; Marhaba R; Ali N; Malubay N; Kawade A; Saul A; Martin LB; Podda A Lancet Infect Dis; 2014 Feb; 14(2):119-29. PubMed ID: 24290843 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of vi-tetanus toxoid conjugated typhoid vaccine (PedaTyph™) in Indian children: School based cluster randomized study. Mitra M; Shah N; Ghosh A; Chatterjee S; Kaur I; Bhattacharya N; Basu S Hum Vaccin Immunother; 2016 Apr; 12(4):939-45. PubMed ID: 26901576 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of typhoid vaccines against culture-confirmed Salmonella Typhi in typhoid endemic countries: a systematic review and meta-analysis. Batool R; Qamar ZH; Salam RA; Yousafzai MT; Ashorn P; Qamar FN Lancet Glob Health; 2024 Apr; 12(4):e589-e598. PubMed ID: 38485426 [TBL] [Abstract][Full Text] [Related]
10. Seroefficacy of Vi Polysaccharide-Tetanus Toxoid Typhoid Conjugate Vaccine (Typbar TCV). Voysey M; Pollard AJ Clin Infect Dis; 2018 Jun; 67(1):18-24. PubMed ID: 29351594 [TBL] [Abstract][Full Text] [Related]
11. A novel Vi-diphtheria toxoid typhoid conjugate vaccine is safe and can induce immunogenicity in healthy Indonesian children 2-11 years: a phase II preliminary report. Medise BE; Soedjatmiko S; Gunardi H; Sekartini R; Satari HI; Hadinegoro SR; Wirahmadi A; Puspita M; Sari RM; Yang JS; Sil A; Sahastrabuddhe S; Bachtiar NS BMC Pediatr; 2020 Oct; 20(1):480. PubMed ID: 33059607 [TBL] [Abstract][Full Text] [Related]
12. Typhoid conjugate vaccine effectiveness in Malawi: evaluation of a test-negative design using randomised, controlled clinical trial data. Liang Y; Driscoll AJ; Patel PD; Datta S; Voysey M; French N; Jamka LP; Henrion MYR; Ndeketa L; Laurens MB; Heyderman RS; Gordon MA; Neuzil KM Lancet Glob Health; 2023 Jan; 11(1):e136-e144. PubMed ID: 36442498 [TBL] [Abstract][Full Text] [Related]
13. Phase 3 Efficacy Analysis of a Typhoid Conjugate Vaccine Trial in Nepal. Shakya M; Colin-Jones R; Theiss-Nyland K; Voysey M; Pant D; Smith N; Liu X; Tonks S; Mazur O; Farooq YG; Clarke J; Hill J; Adhikari A; Dongol S; Karkey A; Bajracharya B; Kelly S; Gurung M; Baker S; Neuzil KM; Shrestha S; Basnyat B; Pollard AJ; N Engl J Med; 2019 Dec; 381(23):2209-2218. PubMed ID: 31800986 [TBL] [Abstract][Full Text] [Related]
14. Vi-Vaccinations Induce Heterogeneous Plasma Cell Responses That Associate With Protection From Typhoid Fever. Cross DL; Verheul MK; Leipold MD; Obermoser G; Jin C; Jones E; Starr JS; Mohorianu I; Blohmke CJ; Maecker HT; Napolitani G; Hill J; Pollard AJ Front Immunol; 2020; 11():574057. PubMed ID: 33424833 [TBL] [Abstract][Full Text] [Related]
15. The safety and immunogenicity of a bivalent conjugate vaccine against Salmonella enterica Typhi and Paratyphi A in healthy Indian adults: a phase 1, randomised, active-controlled, double-blind trial. Kulkarni PS; Potey AV; Bharati S; Kunhihitlu A; Narasimha B; Yallapa S; Dharmadhikari A; Gavade V; Kamat CD; Mallya A; Sarma AD; Goel S; Pisal SS; Poonawalla CS; Venkatesan R; Jones E; Flaxman A; Kim YC; Pollard AJ; Lancet; 2024 Apr; 403(10436):1554-1562. PubMed ID: 38555928 [TBL] [Abstract][Full Text] [Related]
16. Vaccines for preventing typhoid fever. Anwar E; Goldberg E; Fraser A; Acosta CJ; Paul M; Leibovici L Cochrane Database Syst Rev; 2014 Jan; (1):CD001261. PubMed ID: 24385413 [TBL] [Abstract][Full Text] [Related]
17. The Impact of Vaccination and Prior Exposure on Stool Shedding of Salmonella Typhi and Salmonella Paratyphi in 6 Controlled Human Infection Studies. Gibani MM; Voysey M; Jin C; Jones C; Thomaides-Brears H; Jones E; Baker P; Morgan M; Simmons A; Gordon MA; Cerundolo V; Pitzer VE; Angus B; Levine MM; Darton TC; Pollard AJ Clin Infect Dis; 2019 Apr; 68(8):1265-1273. PubMed ID: 30252031 [TBL] [Abstract][Full Text] [Related]
18. Using a Human Challenge Model of Infection to Measure Vaccine Efficacy: A Randomised, Controlled Trial Comparing the Typhoid Vaccines M01ZH09 with Placebo and Ty21a. Darton TC; Jones C; Blohmke CJ; Waddington CS; Zhou L; Peters A; Haworth K; Sie R; Green CA; Jeppesen CA; Moore M; Thompson BA; John T; Kingsley RA; Yu LM; Voysey M; Hindle Z; Lockhart S; Sztein MB; Dougan G; Angus B; Levine MM; Pollard AJ PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004926. PubMed ID: 27533046 [TBL] [Abstract][Full Text] [Related]
19. Safety and Efficacy of a Typhoid Conjugate Vaccine in Malawian Children. Patel PD; Patel P; Liang Y; Meiring JE; Misiri T; Mwakiseghile F; Tracy JK; Masesa C; Msuku H; Banda D; Mbewe M; Henrion M; Adetunji F; Simiyu K; Rotrosen E; Birkhold M; Nampota N; Nyirenda OM; Kotloff K; Gmeiner M; Dube Q; Kawalazira G; Laurens MB; Heyderman RS; Gordon MA; Neuzil KM; N Engl J Med; 2021 Sep; 385(12):1104-1115. PubMed ID: 34525285 [TBL] [Abstract][Full Text] [Related]
20. Six-month follow up of a randomized clinical trial-phase I study in Indonesian adults and children: Safety and immunogenicity of Salmonella typhi polysaccharide-diphtheria toxoid (Vi-DT) conjugate vaccine. Medise BE; Soedjatmiko S; Rengganis I; Gunardi H; Sekartini R; Koesno S; Satari HI; Hadinegoro SR; Yang JS; Excler JL; Sahastrabuddhe S; Puspita M; Sari RM; Bachtiar NS PLoS One; 2019; 14(2):e0211784. PubMed ID: 30759132 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]